Skip to main content

CLL

4
Pipeline Programs
7
Companies
17
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
375%
Small Molecule
125%
+ 8 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
3
EltrombopagPhase 2
OfatumumabPhase 2Monoclonal Antibody
Ofatumumab/HDMPPhase 2
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
ibrutinib, venetoclax, obinutuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04639362Active Not Recruiting85Est. Dec 2028
GSK
GSKLONDON, United Kingdom
3 programs
EltrombopagPHASE_21 trial
OfatumumabPHASE_2Monoclonal Antibody1 trial
Ofatumumab/HDMPPHASE_21 trial
Active Trials
NCT01168921Completed23Est. Mar 2022
NCT01465334Terminated30Est. Jan 2017
NCT01191190Completed21Est. Aug 2012
BeOne Medicines
BeOne MedicinesCA - San Carlos
2 programs
BGB-16673PHASE_31 trial
SonrotoclaxPHASE_35 trials
Active Trials
NCT06846671Recruiting250Est. Feb 2030
NCT07887061Not Yet Recruiting30Est. Jul 2032
NCT07674810Not Yet Recruiting40Est. Apr 2029
+3 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
Treatment Free ObservationN/A1 trial
Active Trials
NCT04694560Withdrawn0Est. Mar 2023
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
TG-1801PHASE_11 trial
Active Trials
NCT04806035Terminated21Est. Jun 2024
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
ZandelisibPHASE_2Small Molecule1 trial
Active Trials
NCT05209308Withdrawn0Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BeOne MedicinesBGB-16673
BeOne MedicinesSonrotoclax
BeOne MedicinesSonrotoclax
BeOne MedicinesSonrotoclax
BeOne MedicinesSonrotoclax
Kyowa Hakko KirinZandelisib
Nordic Pharmaibrutinib, venetoclax, obinutuzumab
GSKOfatumumab
GSKEltrombopag
GSKOfatumumab/HDMP
BeOne MedicinesSonrotoclax
BeOne MedicinesSonrotoclax
BeOne MedicinesSonrotoclax
BeOne MedicinesSonrotoclax
TG TherapeuticsTG-1801

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 1,828 patients across 17 trials

NCT06846671BeOne MedicinesBGB-16673

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Start: Apr 2025Est. completion: Feb 2030250 patients
Phase 3Recruiting
NCT06073821BeOne MedicinesSonrotoclax

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Start: Nov 2023Est. completion: Dec 2032652 patients
Phase 3Active Not Recruiting
NCT07887061BeOne MedicinesSonrotoclax

Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Start: Jan 2027Est. completion: Jul 203230 patients
Phase 2Not Yet Recruiting
NCT07674810BeOne MedicinesSonrotoclax

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

Start: Dec 2026Est. completion: Apr 202940 patients
Phase 2Not Yet Recruiting
NCT07682415BeOne MedicinesSonrotoclax

Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

Start: Jun 2026Est. completion: Aug 203460 patients
Phase 2Not Yet Recruiting
NCT05209308Kyowa Hakko KirinZandelisib

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Start: Nov 2022Est. completion: Mar 20230
Phase 2Withdrawn
NCT04639362Nordic Pharmaibrutinib, venetoclax, obinutuzumab

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Start: Dec 2020Est. completion: Dec 202885 patients
Phase 2Active Not Recruiting
NCT01465334GSKOfatumumab

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Start: Dec 2011Est. completion: Jan 201730 patients
Phase 2Terminated
NCT01168921GSKEltrombopag

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Start: Nov 2010Est. completion: Mar 202223 patients
Phase 2Completed
NCT01191190GSKOfatumumab/HDMP

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

Start: Aug 2010Est. completion: Aug 201221 patients
Phase 2Completed
NCT07770698BeOne MedicinesSonrotoclax

A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia

Start: Dec 2026Est. completion: Sep 203130 patients
Phase 1/2Not Yet Recruiting
NCT05471843BeOne MedicinesSonrotoclax

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Start: Sep 2022Est. completion: Jan 2027125 patients
Phase 1/2Active Not Recruiting
NCT07855991BeOne MedicinesSonrotoclax

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment

Start: Nov 2026Est. completion: Feb 202712 patients
Phase 1Not Yet Recruiting
NCT07628881BeOne MedicinesSonrotoclax

A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults

Start: Jun 2026Est. completion: Sep 202612 patients
Phase 1Completed
NCT04806035TG TherapeuticsTG-1801

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Start: Apr 2021Est. completion: Jun 202421 patients
Phase 1Terminated
NCT04277637BeOne MedicinesSonrotoclax

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Start: Mar 2020Est. completion: May 2027437 patients
Phase 1Active Not Recruiting
NCT04694560AbbVieTreatment Free Observation

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start: Dec 2020Est. completion: Mar 20230
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,828 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.